Similarly, in a study on a mouse model of pancreatic carcinoma with enhanced expression of the EGFR factor, subcutaneous administration of PA-MSHA (2.2 × 1010 cells/mL) in combination with paclitaxel (10 mg/kg, 2 times a week, for 7 weeks) led to cancerous cell apoptosis and growth inhibition [41]. Here, EGFR is linked to exocrine pancreatic carcinoma.